Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TCRR TCR2 Therapeutics (TCRR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About TCR2 Therapeutics Stock (NASDAQ:TCRR) 30 days 90 days 365 days Advanced Chart Ad Angel PublishingWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. Get TCR2 Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.6350-Day Range$1.48▼$1.9852-Week Range$0.82▼$3.88Volume3.91 million shsAverage Volume494,777 shsMarket Capitalization$58.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Read More… What Is the $7,882 Stimulus Payment 2024? (Ad)Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Stock News HeadlinesPoseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comDICE Therapeutics Inc.June 20, 2023 | wsj.comThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This parable teaches us that it’s our duty, and our challenge, to grow our money … to invest it and put it to good use … rather than keeping it stuffed away in a savings account, or wasting it in some frivolous way. In this video, Wall Street expert Charles Mizrahi shows me a secret that has helped me … and tons of other hardworking Americans … learn to invest just like the pros on WallOctober 10, 2024 | Prosperity Research (Ad)Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comSee More Headlines TCRR Stock Analysis - Frequently Asked Questions How were TCR2 Therapeutics' earnings last quarter? TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.06. When did TCR2 Therapeutics IPO? TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. What other stocks do shareholders of TCR2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX) and LogicBio Therapeutics (LOGC). Company Calendar Last Earnings11/10/2021Today10/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCRR CUSIPN/A CIK1750019 Webwww.tcr2.com Phone(617) 949-5200FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.81% Return on Assets-69.35% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.57Miscellaneous Outstanding Shares39,260,000Free Float29,443,000Market Cap$58.10 million OptionableNot Optionable Beta1.95 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:TCRR) was last updated on 10/10/2024 by MarketBeat.com Staff From Our PartnersBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredAI Expert Reveals New PickWhy You Shouldn't Pour All Your Money Into Nvidia Jeff Brown, who predicted Nvidia's rise, warns against pu...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TCR2 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.